Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
S. Abdel-Ghany, N. Elmelegy, A. Mohamed-Hussein, R. Hana (Assiut, Egypt). Emerging prognostic biomarkers in non small cell lung cancer patients: Impact of treatment with nimesulide (COX-2 inhibitor) combined with chemotherapy. Eur Respir J 2011; 38: Suppl. 55, 2800

Member's Comments

No comment yet.

Related content which might interest you: Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Cox-2 inhibitors in the treatment of small cell lung cancer patients Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Efficacy and safety of amurubicin (AMR) for the elderly with refractory relapse small cell lung cancer (SCLC) who had previous treatment Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo). Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 Effects of pretreatment prognostic factors and treatment on survival in advanced nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 431s Year: 2003 The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004 Biological factors predicting response to chemotherapy (CT) in advanced non small cell lung cancer (NSCLC): A feasibility study on the collection of tissue Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010 Histology as a potential clinical predictor of outcome in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and mitomycin (VM) combination chemotherapy Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Can molecular markers (EGFR, ERCC1) serve as screening parameters for adjuvant chemotherapy decision in early staged non-small cell lung cancer patients? Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Endoscopical laser treatment in combined therapy non small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002 Clinical significance of serum cathepsin K level during chemotherapy of lung cancer. Can we use it as a marker of small cell lung cancer? Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008 Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Combination of erlotinib and bevacizumab in non small cell lung cancer patients Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 C-erbB-3 expression in non small cell lung cancer (NSCLC) patients treated by erlotinib Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002 Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC) Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer (ED SCLC) Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Tobacco exposure and survival in non small cell lung cancer patients treated with erlotinib Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009